# Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

> **NCT07389590** · PHASE4 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ublituximab
- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT07389590
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2028-10
- **Final completion:** 2029-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389590, "Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07389590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*